"Every region of the U.S." is affected by opioid epidemic
The National Institutes of Health (NIH) has begun testing an experimental drug that could help opioid addicts deal with the cravings that cause them to continue using the dangerous substance. In Phase I of the clinical trial currently underway at the NIH Clinical Center – researchers will study how the compound ANS-6637 is processed in the body when given with another drug that is processed by the same liver enzyme pathway. The NIH’s National Institute of Allergy and Infectious Diseases (NIAID) is helping to conduct the trial, which is funded through NIH’s Helping to End Addiction Long-Term (HEAL) Initiative, a comprehensive program to accelerate research efforts to stem the growing numbers of people with opioid use disorder (OUD) opioid epidemic.
The NIH’s National Institute of Allergy and Infectious Diseases (NIAID) is helping to conduct the trial, which is funded through NIH’s Helping to End Addiction Long-Term (HEAL) Initiative, a comprehensive program to accelerate research efforts to stem the public health crisis that is the opioid epidemic.